OptimizeRx opened lower at $6.70, compared with its previous close of $8.95. In the last trading session, the stock traded between $6.33 and $8.45. It showed a downward intraday trend.
An investment of $100 made 5 years ago in OptimizeRx is now worth
$ 10.46
Resulting in a loss of
$ 89.54 (89.54%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.32 (-3.52%)
Day High
$8.45
Day Low
$6.33
Day Open
$6.70
Prev Close
$8.95
Volume
11,92,100
1W Return
-11.93%
1M Return
5.06%
3M Return
24.87%
6M Return
39.05%
1Y Return
-45.66%
Market Cap ($ Mn)
163
PE Ratio
33.13
PB Ratio
1.14
PEG Ratio
0.90
ROE
4.25%
ROCE
7.85%
EPS (TTM)
$-0.04
1 Week
-11.93%
1 Month
5.06%
3 Months
24.87%
6 Months
39.05%
9 Months
-6.45%
OptimizeRx Q3FY26 Results: EPS beats, sales guidance cut to $87M-$93M
Q3 EPS of 20 cents beat consensus of 17 cents. FY26 sales guidance cut to $87M-$93M from $95M-$100M. Adjusted EBITDA rose ~23% with margins expanding 900 bps. Shares fell 17.3% to $7.40 post-announcement. B. Riley and Stifel lowered price targets to $10.5 and $11 respectively.
TodayOptimizeRx Q3FY26 Results: Adj. EPS $0.20 beats, shares fall 20%
Shares fell 20.11% to $7.15 in after-hours trading following Q3 results. Adjusted EPS of $0.20 beat consensus estimate of $0.17 by 17.65%. Revenue declined 17% YoY to $21.6 million, missing prior-year levels. Full-year 2026 revenue guidance cut to $87-$93 million from $95-$100 million. Adjusted EBITDA rose 23% to $6.3 million as margins expanded to 29%.
TodayOptimizeRx appoints ex-J&J exec Troy Sarich as advisor
OptimizeRx Corp (NASDAQ: OPRX) appoints Troy Sarich as a company advisor. Sarich brings nearly 30 years of experience in healthcare commercialization and AI. Former Chief Commercial Data Science Officer at Johnson & Johnson. Role focuses on guiding evolution of data and technology offerings.
2mo agoOptimizeRx Q2 adj. EPS beats estimate as sales fall 30% YoY
OptimizeRx reported Q2 2026 adjusted EPS of $0.16, beating estimates by 33%, while revenue fell 30% YoY to $20.5 million. The company reaffirmed full-year guidance and completed a $35 million debt refinancing, paying down $8.3 million in principal since inception. Net revenue retention dropped to 90% from 121%.
3mo agoOptimizeRx names D'Silva as CFO, Favazza as CAO for 2027
OptimizeRx Corp (NASDAQ: OPRX) named Andy D'Silva as CFO and Heather Favazza as CAO, effective January 1, 2027. Outgoing CFO Ed Stelmakh transitions to Chief Financial & Strategy Officer through late 2026 and then Strategic Advisor through 2027. The move underscores the company's succession planning and stable financial strategy.
3mo agoOptimizeRx Latest Results: FY2026 sales guidance affirmed at $95M-$100M
OptimizeRx reaffirmed its FY2026 sales guidance at $95.000 million to $100.000 million. The affirmed range is unchanged and brackets the analyst consensus estimate of $97.427 million. No revision to the outlook was indicated.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $506.04 | +0.32% | $1,05,708.21M | 14.01 | |
| $304.77 | -0.26% | $49,345.01M | 45.36 | |
| $292.97 | +0.93% | $23,316.90M | 10.31 | |
| $72.62 | +0.18% | $14,450.29M | 52.31 | |
| $79.43 | -1.38% | $14,087.55M | - | |
| $142.24 | -0.19% | $13,957.16M | 20.21 | |
| $22.22 | -2.29% | $11,935.03M | 11.93 | |
| $183.50 | +2.35% | $11,542.15M | 15.26 | |
| $186.19 | +0.59% | $10,862.51M | 27.11 | |
| $196.77 | +0.70% | $10,170.65M | 7.00 | |
| $103.03 | -0.49% | $8,522.13M | 34.79 | |
| $50.06 | +1.96% | $7,945.72M | 25.00 |
An investment of $100 made 5 years ago in OptimizeRx is now worth
$ 10.46
Resulting in a loss of
$ 89.54 (89.54%)
Note: Past profits do not guarantee future returns.
